Pam Kushner, MD FAAFP

The panel of experts examines how the CATALYST trial is changing the way primary care clinicians recognize hypercortisolism in patients with difficult-to-control type 2 diabetes.

Patients who keep missing treatment goals despite good therapy may be facing an unrecognized hormonal driver that primary care is now positioned to catch early.